Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

2024 ASCO Annual Meeting


Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We're presenting the results of the CARTITUDE-4 focusing on the patients with one prior line of therapy, with emphasis on the patients with functional high-risk myeloma. Functional high-risk myeloma has long been recognized as those patients who have a progression within 18 months of the transplant or 18 months of the initial therapy. And that's a population that's particularly hard to treat, and is a population that has not been well represented in most randomized clinical trials. CARTITUDE-4 was a trial that compared cellular therapy, cell-to-cell and anti-BCMA autologous CAR-T cell therapy with a standard of care which was DARA-PD, or PVD in patients with one to three prior lines of therapy. And that was a very positive study that actually supported the approval in the U.S. and other jurisdictions of cell-to-cell as a therapy for patients with one to three lines of therapy as long as they were exposed to a proteasome inhibitor and exposed and refracted to lenalidomide. one of the question is I think with everybody's mind is, should we use this powerful therapy even in second line therapy with patients with one prior line? And this abstract helps to answer that. So we had in the overall study, we had 60 patients with one prior line of therapy on the cell-to-cell arm and 60 patients on the control arm. And of those 40 and 39 would meet criteria for functional high risk. And what we saw is for all patients with one prior line of therapy, cell-to-cell greatly reduced the risk of progression or death and led to a much higher rate of response, complete response and MRD negative response. And that effect was also seen. And if anything was magnified on the patient with functional high risk where cell-to-cell led to a more than 70% reduction in the risk of progression and death by leading to deeper and longer lasting responses. Of course, CAR-T cell and cell-to-cell has some unique toxicities such as cytokine release syndrome and ICANS, things that are on the back of everybody's mind as we consider those therapies. And what we saw is for this one prior line of therapy population, including the function of high risk, the rate of grade three or higher adverse events and severe adverse events was very similar between the two arms. When you look at those events of special interest CRS for example, that was very common. About 60% or more of the patients on the cell-to-cell arm developed those adverse events, but very rarely they were of high grade. There was one single case of high-grade CRS. The same thing for ICANs. There was less than 5% among the patients receiving cell-to-cell. And we had essentially one case of Parkinsonism, which is really consistent with the overall safety profile of cell-to-cell. So in general, this abstract give us some very tangible, useful data that patients with one line of therapy who have a lenalidomide refractor myeloma and proteasome inhibitor exposed myeloma do benefit from cell-to-cell over a standard of care. And that benefit is particularly important and robust among the patients with the functional high-risk disease.

Related Videos

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.


Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Prostate Cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).


William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).